{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:54:56Z","timestamp":1787849696406,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["F.N.8\/1\/7\/2019-RMC"],"award-info":[{"award-number":["F.N.8\/1\/7\/2019-RMC"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17214-8","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:36:20Z","timestamp":1759397780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of the tumor microenvironment on survival in anaplastic thyroid carcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1783-7689","authenticated-orcid":false,"given":"Chanchal","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulranjan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Ramakant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaira","family":"Qayoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulshan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"3","key":"17214_CR1","first-page":"239","volume":"36","author":"I Abe","year":"2021","unstructured":"Abe, I. & Lam, A. K. Y. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol. Histopathol. 36(3), 239\u2013248 (2021).","journal-title":"Histol. Histopathol."},{"issue":"6","key":"17214_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"Smallridge, R. C. & Copland, J. A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin. Oncol. R. Coll. Radiol. G B. 22(6), 486\u2013497 (2010).","journal-title":"Clin. Oncol. R. Coll. Radiol. G B."},{"issue":"1","key":"17214_CR3","first-page":"15","volume":"56","author":"B Arneth","year":"2019","unstructured":"Arneth, B. Tumour microenvironment. Med. Kaunas Lith. 56(1), 15 (2019).","journal-title":"Med. Kaunas Lith."},{"issue":"1","key":"17214_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and metabolism in the tumour microenvironment. Cell Metab. 30(1), 36\u201350 (2019).","journal-title":"Cell Metab."},{"issue":"1","key":"17214_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin, M. Z. & Jin, W. L. The updated landscape of tumour microenvironment and drug repurposing. Signal Transduct. Target Ther. 5(1), 166 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"17214_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai, L., Xu, A. & Xu, J. Roles of PD-1\/PD-L1 pathway: Signaling, cancer, and beyond. Adv. Exp. Med. Biol. 1248, 33\u201359 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"17214_CR7","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang, Q. et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol. 13, 964442 (2022).","journal-title":"Front. Immunol."},{"issue":"2","key":"17214_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20(2), 69\u201384 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"17214_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11684-018-0656-6","volume":"12","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. & Weinberg, R. A. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front. Med. 12(4), 361\u2013373 (2018).","journal-title":"Front. Med."},{"issue":"20","key":"17214_CR10","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.3390\/ijms21207624","volume":"21","author":"I Kaszak","year":"2020","unstructured":"Kaszak, I. et al. Role of cadherins in cancer\u2014A review. Int. J. Mol. Sci. 21(20), 7624 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"17214_CR11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.seminoncol.2015.05.012","volume":"42","author":"JL Goldberg","year":"2015","unstructured":"Goldberg, J. L. & Sondel, P. M. Enhancing cancer immunotherapy via activation of innate immunity. Semin. Oncol. 42(4), 562\u2013572 (2015).","journal-title":"Semin. Oncol."},{"key":"17214_CR12","doi-asserted-by":"publisher","first-page":"9235638","DOI":"10.1155\/2020\/9235638","volume":"2020","author":"M Ralli","year":"2020","unstructured":"Ralli, M. et al. Immunotherapy in the treatment of metastatic melanoma: Current knowledge and future directions. J. Immunol. Res. 2020, 9235638 (2020).","journal-title":"J. Immunol. Res."},{"issue":"1","key":"17214_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","volume":"13","author":"R Ruiz-Cordero","year":"2020","unstructured":"Ruiz-Cordero, R. & Devine, W. P. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg. Pathol. Clin. 13(1), 17\u201333 (2020).","journal-title":"Surg. Pathol. Clin."},{"issue":"8","key":"17214_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/08820139.2023.2268656","volume":"52","author":"Y Tao","year":"2023","unstructured":"Tao, Y., Li, P., Feng, C. & Cao, Y. New insights into immune cells and immunotherapy for thyroid cancer. Immunol. Investig. 52(8), 1039\u20131064 (2023).","journal-title":"Immunol. Investig."},{"issue":"5","key":"17214_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/cells10051082","volume":"10","author":"A Singh","year":"2021","unstructured":"Singh, A. et al. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy. Cells 10(5), 1082 (2021).","journal-title":"Cells"},{"key":"17214_CR16","doi-asserted-by":"publisher","first-page":"712107","DOI":"10.3389\/fendo.2021.712107","volume":"12","author":"P Adam","year":"2021","unstructured":"Adam, P. et al. FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: Evaluation of the preclinical rationale. Front Endocrinol. 12, 712107 (2021).","journal-title":"Front Endocrinol."},{"issue":"1","key":"17214_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3892\/ol.2021.12814","volume":"22","author":"S Cameselle-Garc\u00eda","year":"2021","unstructured":"Cameselle-Garc\u00eda, S. et al. PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study. Oncol. Lett. 22(1), 553 (2021).","journal-title":"Oncol. Lett."},{"issue":"1","key":"17214_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","volume":"64","author":"S Cantara","year":"2019","unstructured":"Cantara, S. et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 64(1), 122\u2013129 (2019).","journal-title":"Endocrine"},{"issue":"23","key":"17214_CR19","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila, J. et al. PD-1 blockade in anaplastic thyroid carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 38(23), 2620\u20132627 (2020).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"17214_CR20","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar, A. V. et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: Results from a retrospective study. J. Clin. Endocrinol. Metab. 102(6), 1943\u20131950 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"17214_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers15010179","volume":"15","author":"J Yuan","year":"2022","unstructured":"Yuan, J. & Guo, Y. Targeted therapy for anaplastic thyroid carcinoma: Advances and management. Cancers 15(1), 179 (2022).","journal-title":"Cancers"},{"issue":"2","key":"17214_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn, S. et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr. Relat. Cancer 24(2), 97\u2013106 (2017).","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"17214_CR23","first-page":"716","volume":"109","author":"KS McCarty","year":"1985","unstructured":"McCarty, K. S., Miller, L. S., Cox, E. B., Konrath, J. & McCarty, K. S. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109(8), 716\u2013721 (1985).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"17214_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12885-016-2429-4","volume":"16","author":"M Carlberg","year":"2016","unstructured":"Carlberg, M., Hedendahl, L., Ahonen, M., Koppel, T. & Hardell, L. Increasing incidence of thyroid cancer in the Nordic countries with main focus on Swedish data. BMC Cancer 16(1), 426 (2016).","journal-title":"BMC Cancer"},{"issue":"4","key":"17214_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato, M. et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4), 264\u2013272 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"17214_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12022-013-9248-9","volume":"24","author":"HR Harach","year":"2013","unstructured":"Harach, H. R., Gal\u00edndez, M., Campero, M. & Ceballos, G. A. Undifferentiated (anaplastic) thyroid carcinoma and iodine intake in Salta. Argentina. Endocr. Pathol. 24(3), 125\u2013131 (2013).","journal-title":"Argentina. Endocr. Pathol."},{"issue":"5","key":"17214_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/ijmr.IJMR_1717_18","volume":"148","author":"K Yadav","year":"2018","unstructured":"Yadav, K. & Pandav, C. S. National iodine deficiency disorders control programme: Current status & future strategy. Indian J. Med. Res. 148(5), 503\u2013510 (2018).","journal-title":"Indian J. Med. Res."},{"issue":"6","key":"17214_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1089\/thy.2010.1647","volume":"20","author":"PPA Smyth","year":"2010","unstructured":"Smyth, P. P. A. Iodine and anaplastic thyroid carcinoma. Thyroid Off. J. Am. Thyroid Assoc. 20(6), 581\u2013582 (2010).","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"2","key":"17214_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2478\/raon-2020-0023","volume":"54","author":"N Besic","year":"2020","unstructured":"Besic, N. & Gazic, B. Dietary iodine intake, therapy with radioiodine, and anaplastic thyroid carcinoma. Radiol. Oncol. 54(2), 187\u2013193 (2020).","journal-title":"Radiol. Oncol."},{"issue":"2","key":"17214_CR30","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/jcrt.jcrt_1471_22","volume":"19","author":"M Boruah","year":"2023","unstructured":"Boruah, M. et al. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy. J. Cancer Res. Ther. 19(2), 312 (2023).","journal-title":"J. Cancer Res. Ther."},{"issue":"4","key":"17214_CR31","doi-asserted-by":"publisher","first-page":"211991","DOI":"10.1098\/rsos.211991","volume":"9","author":"TH Tran","year":"2022","unstructured":"Tran, T. H. & Phuong Tran, T. T. Targeting the PD-1\/PD-L1 axis for cancer treatment: a review on nanotechnology. R. Soc. Open Sci. 9(4), 211991 (2022).","journal-title":"R. Soc. Open Sci."},{"issue":"7","key":"17214_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/jpm12071073","volume":"12","author":"S Marletta","year":"2022","unstructured":"Marletta, S. et al. Atlas of PD-L1 for pathologists: Indications, scores, diagnostic platforms and reporting systems. J. Pers. Med. 12(7), 1073 (2022).","journal-title":"J. Pers. Med."},{"issue":"11","key":"17214_CR33","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","volume":"22","author":"L Pai-Scherf","year":"2017","unstructured":"Pai-Scherf, L. et al. FDA approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: First-line therapy and beyond. Oncologist 22(11), 1392\u20131399 (2017).","journal-title":"Oncologist"},{"issue":"7","key":"17214_CR34","doi-asserted-by":"publisher","first-page":"e22567","DOI":"10.1371\/journal.pone.0022567","volume":"6","author":"B Caillou","year":"2011","unstructured":"Caillou, B. et al. Tumour-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS ONE 6(7), e22567 (2011).","journal-title":"PLoS ONE"},{"issue":"4","key":"17214_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4132\/jptm.2015.06.01","volume":"49","author":"KY Jung","year":"2015","unstructured":"Jung, K. Y. et al. Cancers with higher density of tumour-associated macrophages were associated with poor survival rates. J. Pathol. Transl. Med. 49(4), 318\u2013324 (2015).","journal-title":"J. Pathol. Transl. Med."},{"issue":"1","key":"17214_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mc.23268","volume":"60","author":"J Lv","year":"2021","unstructured":"Lv, J. et al. M2-like tumour-associated macrophages-secreted Wnt1 and Wnt3a promotes dedifferentiation and metastasis via activating \u03b2-catenin pathway in thyroid cancer. Mol. Carcinog. 60(1), 25\u201337 (2021).","journal-title":"Mol. Carcinog."},{"issue":"4","key":"17214_CR37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1677\/ERC-08-0036","volume":"15","author":"M Ryder","year":"2008","unstructured":"Ryder, M., Ghossein, R. A., Ricarte-Filho, J. C. M., Knauf, J. A. & Fagin, J. A. Increased density of tumour-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 15(4), 1069\u20131074 (2008).","journal-title":"Endocr. Relat. Cancer"},{"issue":"7","key":"17214_CR38","doi-asserted-by":"publisher","first-page":"e22567","DOI":"10.1371\/journal.pone.0022567","volume":"6","author":"B Caillou","year":"2011","unstructured":"Caillou, B. et al. Tumour-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS ONE 6(7), e22567 (2011).","journal-title":"PLoS ONE"},{"issue":"5","key":"17214_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000516263","volume":"88","author":"R Kanematsu","year":"2021","unstructured":"Kanematsu, R. et al. Evaluation of E-cadherin and \u03b2-catenin immunoreactivity for determining undifferentiated cells in anaplastic thyroid carcinoma. Pathobiol. J. Immunopathol. Mol. Cell Biol. 88(5), 351\u2013358 (2021).","journal-title":"Pathobiol. J. Immunopathol. Mol. Cell Biol."},{"issue":"2","key":"17214_CR40","first-page":"450","volume":"21","author":"E Tsiambas","year":"2016","unstructured":"Tsiambas, E. et al. E-cadherin\/\u03b1-catenin deregulated co-expression in thyroid carcinoma based on tissue microarray digital image analysis. J. BUON Off. J. Balk Union Oncol. 21(2), 450\u2013455 (2016).","journal-title":"J. BUON Off. J. Balk Union Oncol."},{"issue":"11","key":"17214_CR41","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","volume":"10","author":"Q Yang","year":"2020","unstructured":"Yang, Q. et al. The role of tumour-associated macrophages (TAMs) in tumour progression and relevant advance in targeted therapy. Acta Pharm. Sin. B. 10(11), 2156\u20132170 (2020).","journal-title":"Acta Pharm. Sin. B."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17214-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:03:24Z","timestamp":1759403004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17214-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17214"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17214-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34381"}}